Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...
Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
Berlin, Germany (ots/PRNewswire) - - Global Survey Highlights Misunderstandings About Causes and Treatment of Constipation - Not for use or publication in the USA Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show ...
Toronto (ots/PRNewswire) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were announced today at the 16th International AIDS Conference (IAC) in Toronto, Canada. Results from this 48-week analysis show that patients achieved virologic ...
Ludwigshafen, Germany (ots/PRNewswire) - - BASF CEO Hambrecht: 'We started the integration process.' BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced the successful completion of its acquisition of Engelhard Corporation (NYSE: EC). "Together with the Engelhard team we have started the integration process in which our customers continue to be the key priority," ...
Ludwigshafen, Germany (ots/PRNewswire) - - BASF Announces Completion of Subsequent Offering Period BASF Aktiengesellschaft (Frankfurt: BAS; NYSE: BF [ADR]; LSE: BFA; SWX: AN) today announced the completion of the subsequent offering period for the outstanding shares of Engelhard. As of 8:00 p.m. New York City time on June 8, 2006, a total of 113,489,680 shares, representing more than 90% of Engelhard's (NYSE: ...
Ludwigshafen, Germany (ots/PRNewswire) - - BASF-CEO Hambrecht: 'Special day for BASF and Engelhard, more innovative solutions for customers.' - Subsequent offering period to expire on June 8, 2006 BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced the expiration of its initial tender offer period to purchase all of the outstanding shares of Engelhard Corporation ...
Ludwigshafen, Germany (ots/PRNewswire) - - Engelhard Recommends That Engelhard's Shareholders Accept BASF's Offer - BASF CEO Hambrecht: "Crucial step towards acquisition of Engelhard." BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) announced today that it signed a definitive agreement with Engelhard Corporation (NYSE: EC). According to the agreement, Engelhard will recommend that Engelhard shareholders tender their shares to BASF ...
Ludwigshafen, Germany (ots/PRNewswire) - BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced that Institutional Shareholder Services (ISS) has recommended that Engelhard's shareholders vote for BASF's five nominees for election to Engelhard's Board of Directors at the June 2 Annual Shareholders' Meeting. ISS is a ...
Ingelheim, Germany (ots/PRNewswire) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in Los Angeles. The survey, sponsored by Boehringer Ingelheim, offers new insights into the incidence of constipation and shows that ...
Ludwigshafen, Germany (ots/PRNewswire) - - BASF CEO Hambrecht: 'This is our last, best and final offer.' BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced that it has raised its all-cash offer for Engelhard Corporation (NYSE: EC) to US$39 per share from its previous offer of US$38 per share. "We are confident that Engelhard's shareholders will recognize the superior ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25% of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international gastroenterology congress Digestive Disease Week (DDW) 2006 ...
Ludwigshafen, Germany (ots/PRNewswire) - - BASF proposes nominees for a majority of the Engelhard Board of Directors BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced that, through its wholly owned subsidiary, Iron Acquisition Corporation, it has extended the expiration date of its tender offer with the Securities ...
Ludwigshafen, Germany (ots/PRNewswire) - - BASF's All-Cash Bid Provides Greater Value and Certainty than Engelhard's Proposal BASF is considering all its options after Engelhard's Board of Directors rejected an increased cash offer of US$38 per share proposed by BASF, as part of a negotiated merger transaction, and elected instead to pursue a partial share buyback plan. Following a preliminary review of Engelhard's proposed transaction, BASF continues to ...
Ludwigshafen, Germany (ots/PRNewswire) - BASF Aktiengesellschaft (Frankfurt: BAS; NYSE: BF [ADR]; LSE: BFA; SWX: AN) today announced that, through its wholly owned subsidiary, Iron Acquisition Corporation, it has extended the expiration date of its US$37 cash tender offer for all of the issued and outstanding shares of common stock of Engelhard Corporation (NYSE: EC) to 5:00 p.m., New York City time, on Friday, ...
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Professional Media Boehringer Ingelheim announced today that that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Sifrol(R) / Mirapexin(R) ...
Ludwigshafen, Germany (ots) - BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN), the world's leading chemical company, today announced that it is commencing a cash tender offer for all of the outstanding shares of common stock of Engelhard Corporation (NYSE: EC) for US$37.00 net per share. BASF's price represents a 23% premium above the December 20, 2005 closing price of Engelhard's ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - New hope for HIV/AIDS patients: APTIVUS(R) outperforms several commonly prescribed drugs in the protease inhibitor (PI) class DUBLIN, Ireland, November 21 /PRNewswire/ -- - Experts Emphasize Need for Effective Therapy in Response to Increased Prevalence of HIV/AIDS throughout Europe At the 10th European AIDS Clinical Society (EACS) conference, experts ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...
Berlin, Germany (ots/PRNewswire) - - For Healthcare Professional Journalists - Not for distribution to US media - Randomised, Placebo-Controlled Study Shows Discontinuation of Pramipexole Leads to Rapid Worsening of Symptoms - Two new, randomised, placebo-controlled studies presented this week at the ...
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
INGELHEIM, Germany,, February 28 (ots/PRNewswire) - - Tipranavir/r More Effective Than Lopinavir/r in Large-Scale Studies of Treatment-Experienced HIV-Positive Patients New data from multiple analyses presented last week at the 12th Conference on Retroviruses and Opportunistic Infections support the efficacy of the investigational non-peptidic protease ...
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
Ludwigshafen (ots) - - Further strong increase in sales and EBIT before special items - Sales prices increased to reflect higher raw materials costs - Risks due to high raw materials prices - Outlook for full year 2004: - Significant increase in sales and EBIT before special items - Premium will be earned on cost of capital BASF continued on its successful course in the third quarter of 2004 and again posted excellent ...
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...
Ludwigshafen, Germany (ots) - - Volume growth in all segments - Chemicals activities improve significantly - Cash flow increases further - High raw materials have negative impact - Outlook for full year 2004: Higher EBIT before special items expected BASF again showed that it can maintain a good course, even in stormy economic weather. "We perform consistently thanks to our ...
Ludwigshafen (ots) - - Sales rise substantially in 2003 despite negative currency effects - EBIT before special items higher than in previous year - Fourth quarter substantially better than expected - Cash flow at record level - Agricultural Products & Nutrition increases sales and earnings BASF's figures for 2003 clearly show that the tremendous hard work by the company's ...
Freudenberg & Co. Kommanditgesellschaft
Weinheim/Munich (ots) - Klüber remains key company / Chem-Trend rounds off portfolio Freudenberg & Co., Weinheim, Germany, has acquired the US release agents company Chem-Trend, of Howell, Michigan. The takeover reinforces the specialities operations of the diversified industrial Group. In order to consolidate the lubrication activities Freudenberg has formed the new business group, "Freudenberg ...
